A jury sided with Gilead Sciences in a dispute over whether the government could claim a share of profits from drugs seen as crucial to ending the H.I.V. epidemic.
Style and beauty
Style and beauty
A jury sided with Gilead Sciences in a dispute over whether the government could claim a share of profits from drugs seen as crucial to ending the H.I.V. epidemic.
